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Muir±Torre syndrome is an autosomal-dominant
inherited disorder predisposing to both sebaceous
skin tumors and internal neoplasms. In a signi®cant
proportion of Muir±Torre syndrome patients skin
tumors exhibit microsatellite instability as a hallmark
of hereditary nonpolyposis colorectal cancer. Most
individuals predisposed to hereditary nonpolyposis
colorectal cancer harbor a germline mutation in the
DNA mismatch repair genes MSH2 or MLH1. In
Muir±Torre syndrome the vast majority of germline
mutations have been identi®ed in MSH2.
Microsatellite instability in tumor tissue develops
after somatic inactivation of the corresponding sec-
ond mismatch repair allele (``second hit''). So far,
the mechanisms of somatic inactivation of the sec-
ond allele in microsatellite instability positive tumors
from patients with known mismatch repair germline
mutations are not well understood. We examined
whether allele loss (loss of heterozygosity) is a fre-
quent mechanism for inactivation of the second
MSH2 allele in a sample of nine microsatellite
instability positive skin tumors from eight unrelated
Muir±Torre patients with known MSH2 germline
mutations. Loss of heterozygosity was determined
using microsatellite markers or heteroduplex analy-
sis, respectively. Only one of the nine skin tumors
exhibited loss of heterozygosity at the MSH2 locus.
Thus, we could show in a sample of sebaceous
tumors from patients with genetically proven Muir±
Torre syndrome that loss of heterozygosity most
probably is not the preferred mode of somatic inacti-
vation of the second MSH2 allele. Key words: DNA
mismatch repair/hereditary nonpolyposis colorectal cancer/
hMSH2 germline mutation/loss of heterozygosity/microsa-
tellite instability. J Invest Dermatol 116:463±465, 2001
M
uir±Torre syndrome (MTS) (OMIM 158320) is
a rare autosomal-dominant inherited disorder
predisposing to both skin tumors (especially
sebaceous gland tumors) and internal neoplasms
(mostly colorectal carcinomas) (Schwartz and
Torre, 1995). In a high proportion of MTS patients, skin tumors
exhibit microsatellite instability (MSI) (Honchel et al, 1994), a
characteristic feature of tumors related to hereditary nonpolyposis
colorectal cancer (OMIM 120435 and 120436). Most hereditary
nonpolyposis colorectal cancer patients harbor a germline mutation
in one of the DNA mismatch repair (MMR) genes MSH2 or
MLH1. In MTS the vast majority of germline mutations (19 of 22
published worldwide) have been identi®ed in MSH2 (Kolodner
et al, 1994; Liu et al, 1994; Kruse et al, 1996, 1998; Esche et al, 1997;
Bapat et al, 1999; DoreÂ et al, 1999; Godard et al, 1999; Lynch et al,
1999; RuÈtten et al, 1999; Caldes et al, 2000; this report), whereas
only three mutations were found in MLH1 (Bapat et al, 1996; Kruse
et al, 1998, 1999; RuÈtten et al, 1999). Fifteen of 19 MSH2 germline
mutations and all three MLH1 germline mutations are either
frameshift or non-sense mutations, leading to truncated MMR gene
products.
It was considered that in tumors MSI develops after somatic
inactivation of the corresponding second MMR allele (``second
hit''), analogous to inactivation of tumor suppressor function in
hereditary tumor predisposition syndromes, e.g., neuro®bromatosis
or tuberous sclerosis (Green et al, 1994; Colman et al, 1995; Kluwe
et al, 2000). According to Knudson's ``two-hit'' hypothesis
(Knudson, 1971) in hereditary tumors one allele of a tumor
suppressor gene is constitutionally inactivated whereas the second
allele is subsequently inactivated (``second hit'') at the somatic level.
In tumor suppressor genes the ``second hit'' is frequently
accomplished by a large deletion encompassing the wild-type allele
[loss of heterozygosity (LOH)].
So far, there are only few studies about mechanisms of somatic
inactivation of the second allele in MSI positive tumors from
patients with known MMR germline mutations.
This study was performed in a sample of MSI positive skin
tumors from MTS patients with known MSH2 germline muta-
tions. The aim of this study was to examine whether LOH is the
preferred mechanism for inactivation of the second MSH2 allele in
MTS related skin tumors.
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MATERIALS AND METHODS
Patients and tumor samples We selected nine skin tumors with high
MSI from eight unrelated MTS patients with known germline mutations in
MSH2 (see Table I). Patient 62 is a 34 y old otherwise healthy female from
an hereditary nonpolyposis colorectal cancer kindred, diagnosed with a
sebaceous carcinoma of the skull. Clinical data of the other seven patients
are described in detail elsewhere (Kruse et al, 1998).
Isolation of genomic DNA Ethylenediamine tetraacetic acid
anticoagulated blood samples were taken from all MTS patients who had
given informed consent. Normal DNA was extracted from the peripheral
blood by salting out (Miller et al, 1988). Tumor DNA was extracted from
microdissected paraf®n-embedded tumor tissue by use of the QIAamp
tissue kit (Qiagen, Hilden, Germany).
Assessment of LOH
Typing with microsatellite markers In one part of the tumor DNA we
assessed LOH by examining the DNA from tumors and
corresponding normal tissue with three microsatellite markers
located within a region of about 4 cM, which includes the MSH2
gene on chromosome 2p16 (D2S2378 and D2S2240 proximal of
MSH2, D2S123 distal of MSH2 according to the Marsh®eld map:
http://research.marsh®eldclinic.org/genetics).
One primer of each primer pair was labeled with ABI ¯uorescence dye.
Polymerase chain reaction (PCR) products were separated by electrophor-
esis on an ABI 377 automated sequencer (Applied Biosystems, Weiterstadt,
Germany). Allele loss was scored comparing ¯uorescence signals of tumor
DNA with DNA from normal tissue. Both PCR and electrophoresis steps
were performed twice.
Non-radioactive heteroduplex analysis As an alternative method for
LOH assessment we used heteroduplex analysis in tumor DNA on
PCR fragments harboring the known MSH2 germline mutation. In
detail, for PCR ampli®cation of MSH2 fragments from tumor
DNA we used the primer pairs and PCR conditions described by
Kolodner et al (1994). Nonisotopic heteroduplex analyses on
nondenaturing 10% polyacrylamide gels were performed as
described elsewhere (Mandl et al, 1994). Each reaction was
performed twice.
RESULTS
We assessed LOH at the MSH2 locus in a sample of nine MSI
positive skin tumors from eight unrelated MTS patients with
known MSH2 germline mutations (Table I).
We examined LOH in three of the nine tumors using the highly
polymorphic microsatellite markers D2S123, D2S2378, and
Table I. Examination of nine MSI positive skin tumors from eight MTS patients with known MSH2 germline mutations for
loss of heterozygosity at the MSH2 locusa
Patient MSH2 germline Skin tumor MSI Method for LOH at MSH2
mutation LOH assessment
130 Exon 2: 289ins22bp Sebaceous adenoma 4/6 HD ±
130 Exon 2: 289ins22bp Sebaceous epithelioma 4/4 HD ±
MTS-K10 Exon 3: 380delAT Sebaceous epithelioma 2/6 MM +
MTS-K2 Exon 10: 1576delA Sebaceous epithelioma 5/6 HD ±
132 Exon 11: 1676delT Cystic sebaceous adenoma 6/7 HD ±
167 Exon 11: 1699delAAACA Squamous cell carcinoma 4/7 HD ±
(keratoacanthoma type)
133 Exon 12: 1809delT Cystic sebaceous adenoma 4/5 HD ±
MTS-K8 Exon 13: 2015delT Sebaceous adenoma 7/9 MM ±
62 Exon 13: C697F Sebaceous carcinoma 5/6 MM ±
aMSI, Microsatellite instability (unstable markers/all examined markers); MM, Ampli®cation of microsatellite markers; HD, heteroduplex analysis; ±, no loss of
heterozygosity; +, loss of heterozygosity.
Figure 1. Assessment of LOH at the MSH2 locus in tumor DNA by
use of microsatellite markers located in close vicinity of the MSH2
gene. Electropherograms of PCR-ampli®ed microsatellite marker D2S123
from normal DNA and from tumor DNA (SE, sebaceous epithelioma) of
patient MTS-K10 showing LOH in tumor DNA.
Figure 2. Assessment of loss of MSH2 heterozygosity by hetero-
duplex analysis. PCR fragments of the exons bearing the MSH2 germline
mutations were examined by electrophoresis on nondenaturing 10%
polyacrylamide gel and visualized by silver staining. PCR fragments from
controls (lanes 1±4), normal tissue (lane 5), and typical MSI positive
sebaceous tumors (lane 6: SE, sebaceous epithelioma; lane 7: SA, sebaceous
adenoma) from an MTS patient (no. 130) with a germline mutation in
exon 2 of the MSH2 gene (289ins22 bp). Lanes 6 and 7 show strong
heteroduplex bands, as seen in lane 5 (DNA from peripheral leukocytes),
indicating the presence of both alleles of MSH2 in tumor tissue.
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D2S2240 closely ¯anking the MSH2 region (see Fig 1). All three
patients were heterozygous for these markers. Only one of the
tumors (a sebaceous epithelioma of patient MTS-K10) showed
LOH with marker D2S123 (Fig 1).
In six tumors from ®ve MTS patients we used heteroduplex
analysis as an alternative method for assessing LOH in MSH2. This
method has been successfully used in hereditary breast cancer
(Mansukhani et al, 1997). We examined all six tumor DNA by
heteroduplex analysis of the exons harboring the germline mutation
and obtained the same strong heteroduplex bands that were seen in
corresponding normal DNA (Fig 2). These observations demon-
strate that two alleles are present in all six tumor tissues.
Taken together, only one of the nine skin tumors showed loss of
the second allele at the MSH2 locus whereas in eight of nine skin
tumors from MSH2-de®cient MTS patients the second MSH2
allele is still present (Table I).
DISCUSSION
In tumorigenesis the ``second hit'' in tumor suppressor genes is
often accomplished by a deletion of the second allele (LOH). The
present results suggest that in sebaceous tumors from MTS patients
with germline MSH2 mutations, somatic inactivation of the second
MSH2 allele by LOH is a rare event.
So far, there are only few studies on the mechanisms of somatic
inactivation of the second allele in MSI positive visceral tumors
from patients with known MMR germline mutations. These studies
led to con¯icting results. Lu et al (1996) detected LOH of the
MSH2 gene in four and somatic mutations in one among eight
colorectal carcinomas of patients with MSH2 germline mutations.
TannergaÊrd et al (1997) showed that the inactivation of the wild-
type allele of MLH1 in six of seven colorectal carcinomas from
patients with known MLH1 germline mutations occurred through
LOH and not through a somatic point mutation. Wang et al (1997)
identi®ed the same somatic mis-sense MLH1 mutation in colorectal
carcinomas from two hereditary nonpolyposis colorectal cancer
patients with different MLH1 germline mutations.
Analyses for LOH at the MSH2 and MLH1 loci in sporadic
colorectal carcinomas with MSI were performed by Tomlinson et al
(1996). They demonstrated that LOH at MSH2 is a rare event in
sporadic colorectal carcinomas: only two of 22 (9%) tumors showed
LOH at MSH2, whereas LOH at MLH1 was found in seven of 17
(41%) colorectal carcinomas. LOH studies on MSI positive sporadic
colorectal carcinomas performed by Benachenhou et al (1998)
revealed hemizygous deletions at both MMR loci only rarely, with
a similar proportion of MLH1 and MSH2: in six of 35 (17%)
informative cases at MLH1 and in four of 27 (15%) at MSH2. In
contrast to our study, however, including only patients with known
MSH2 germline mutations, the frequency of MSH2 germline
mutations had not been assessed in these studies.
To date, only MSI positive sebaceous tumors from MTS patients
with unknown MMR germline mutations have been examined for
the presence of LOH (Peris et al, 1997). These authors reported
LOH at D2S119, a marker located in the vicinity of MSH2, in two
of six sebaceous tumors from two MTS patients.
In summary, we examined nine sebaceous tumors from eight
unrelated MTS patients with known MSH2 germline mutations for
LOH at the MSH2 locus. All the tumors exhibited MSI. Only one
of nine sebaceous tumors showed LOH. Thus, we demonstrated, in
a sample of sebaceous tumors from patients with genetically proven
MTS, that LOH is not the preferred mode of somatic inactivation
of the second MSH2 allele.
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